|
Aspirin in Subclinical Coronary Artery Disease: A Pilot Randomised Controlled Trial
RECRUITINGPhase 3Sponsored by Montreal Heart Institute
Actively Recruiting
PhasePhase 3
SponsorMontreal Heart Institute
Started2026-07-21
Est. completion2027-07-21
Eligibility
Age40 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07524335
Summary
In patients with subclinical coronary artery disease, the ASCAD-P study aims to assess the feasibility of a larger phase 3 pragmatic randomized controlled trial comparing prescription versus no prescription of low-dose aspirin in routine clinical practice.
Eligibility
Age: 40 Years+Healthy volunteers accepted
Inclusion Criteria: 1. Documented coronary atherosclerosis, as defined by one of the following criteria: 1. Coronary artery calcium (CAC) score \> 0; 2. Cardiac CT angiography (CCTA) / CoroScan: lesions \<70% in the right coronary (RCA), left anterior descending (LAD), and circumflex (Cx) arteries or their branches, and \<50% in the left main coronary artery; 3. Coronary angiography: lesions \<70% in the right coronary (RCA), left anterior descending (LAD), and circumflex (Cx) arteries or their branches, and \<50% in the left main coronary artery; if performed, physiological coronary assessments (FFR, dPR, iFR, etc.) and intracoronary imaging (IVUS or OCT) must be negative for significant disease. 2. Willing and able to provide informed consent and comply with study procedures Exclusion Criteria: 1. History of myocardial infarction (MI), coronary revascularization, stroke, transient ischemic attack (TIA), or peripheral arterial revascularization procedure; 2. Current prescription or clear indication for aspirin, low-molecular-weight heparin (LMWH), direct oral anticoagulants, or any other antithrombotic medication; 3. Clear contraindication to aspirin; 4. History of significant bleeding within the past year; 5. Severe illness with limited life expectancy (i.e., \<5 years); 6. Any condition that, in the investigator's judgment, would make participation unsafe for the patient.
Conditions3
Coronary Artery DiseaseHeart DiseaseSubclinical Atherosclerotic Cardiovascular Disease
Interventions2
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 3
SponsorMontreal Heart Institute
Started2026-07-21
Est. completion2027-07-21
Eligibility
Age40 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07524335